Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Cardiology

The Long View: Monitoring Your Heart Over a Lifetime

At a Glance

Familial hypercholesterolemia causes high LDL cholesterol from birth, so long-term care may include Lp(a) testing, selected monitoring of the aortic valve and arteries, and control of blood pressure and other risks; a zero calcium score does not end needed treatment.

Living with Familial Hypercholesterolemia (FH) is about more than just a single blood test; it is about managing a lifetime of risk. Because your body has been exposed to high cholesterol since birth—a concept doctors call LDL-years—your heart and arteries require a different kind of long-term “maintenance” than the average person [1][2].

Beyond the Arteries: The Aortic Valve

While most people think of “high cholesterol” as a risk for heart attacks, in FH, the excess cholesterol can also settle in the aortic valve—the heart’s main exit door [3].

  • Aortic Stenosis: Over time, cholesterol and calcium can build up on this valve, causing it to become stiff and narrow (stenosis) [4].
  • HeFH Risk: People with HeFH have been reported to be about 8 times more likely than the general population to develop aortic stenosis, though absolute risk varies [3].
  • HoFH Risk: In the homozygous form, this risk is much higher and can appear in childhood. It may involve not just the valve itself but also the area just above it (the aortic root) [5][6].

Because of this, periodic echocardiograms (ultrasounds of the heart) are a vital part of long-term monitoring for some patients. However, routine echocardiograms are not automatically required for every child with HeFH; they are particularly important in HoFH or when there is known aortic-root/valve disease or relevant symptoms [1].

Lipoprotein(a): The “Second” Genetic Risk

Many people with FH also inherit high levels of another sticky particle called Lipoprotein(a), or Lp(a) [7].

  • A Double Burden: If you have both FH and high Lp(a), your risk for heart disease is significantly higher than having either condition alone [8][9].
  • Monitoring: Guidelines recommend that everyone with FH have their Lp(a) level checked at least once [10].
  • Management: While standard diet and exercise have little effect on Lp(a), knowing it is high allows your doctor to be even more aggressive in lowering your LDL and managing other risk factors like blood pressure [10][11].

Why Standard “Risk Scores” Don’t Work

You may have seen online calculators that predict your 10-year risk of a heart attack. For people with FH, these tools are often inaccurate because they were designed for people whose cholesterol rose slowly as they aged, not for those who have had high levels since birth [12][13].

Instead, specialists may use FH-specific tools validated in certain adult cohorts, like the SAFEHEART-RE or FH-Risk-Score [14][15]. These calculators can take into account your specific genetic mutation, your untreated LDL levels, and your Lp(a) to help give a more accurate picture of your health, though they do not replace clinical assessment and may not be appropriate for children [14].

Advanced Imaging: Seeing the Invisible

To help get a more accurate picture of an adult’s cardiovascular health, doctors may selectively use specialized scans that involve radiation:

  • Coronary Calcium Scoring (CAC): This CT scan looks for hard calcium deposits in the heart’s arteries [16]. In adults with HeFH, a high score can show that treatment needs to be intensified [13]. However, a score of “zero” does not justify stopping indicated treatment, as early cholesterol buildup (plaque) may not yet be calcified [13].
  • CT Angiography (CTA): This provides a detailed 3D map of the arteries and the aortic root, helping doctors see “soft” plaque before it hardens, and involves contrast dye [17][18].

Both are selective adult tests and are not routine screening tests for children.

Managing the Psychological Journey

Being a “patient for life” can be heavy. It is common for people with FH to experience scan anxiety—the stress that builds up before a blood test or imaging appointment [19].

  • Normalizing the Experience: Anxiety and depressive symptoms are reported in nearly 1 in 3 people with FH [19].
  • Empowerment through Action: Framing these tests as “safety checks” rather than “disaster searches” can help [20]. Early treatment in childhood substantially lowers the risk of heart events by the time a person reaches middle age [20][21]. While early treatment does not eliminate risk entirely, it transforms the long-term outlook.

Your care team is there to manage your heart, but they should also be a resource for your mental well-being. Don’t hesitate to ask for support in navigating the emotional side of this genetic journey [22][23].

Common questions in this guide

Why does familial hypercholesterolemia require heart monitoring over a lifetime?
FH can keep LDL cholesterol high from birth, so the heart and arteries may be exposed to cholesterol for many years. Ongoing care helps clinicians track cardiovascular risk, check for aortic valve or aortic-root problems when appropriate, and adjust risk-reducing treatment.
How often should someone with FH have an echocardiogram?
There is no single schedule for everyone. Routine echocardiograms are not automatically needed for every child with heterozygous FH, but they are especially important for people with homozygous FH, known aortic valve or aortic-root disease, or relevant symptoms; a clinician should set the schedule.
Why is Lp(a) tested in people with familial hypercholesterolemia?
Lp(a) is an inherited cholesterol-related particle that can add to heart risk when it is high. Guidelines recommend checking it at least once in people with FH; if the level is elevated, clinicians may focus more strongly on lowering LDL cholesterol and controlling blood pressure and other risks.
Can I use a standard 10-year heart-risk calculator if I have FH?
Standard calculators may underestimate or otherwise misrepresent risk in FH because they were designed for cholesterol levels that rise with age, not lifelong elevation. For some adults, a specialist may use an FH-specific tool such as SAFEHEART-RE or FH-Risk-Score, but these tools do not replace clinical assessment and may not apply to children.
What does a zero coronary calcium score mean if I have FH?
A zero CAC score means the scan did not detect calcified plaque in the coronary arteries at that time. It does not rule out early or noncalcified plaque and does not mean that indicated FH treatment should be stopped; CAC testing is generally selective rather than routine, especially in children.
How can I cope with anxiety about FH blood tests and scans?
Scan anxiety and depressive symptoms are common concerns for people living with FH. Tell your care team if worry affects sleep or daily life, and ask about a counselor or support group; viewing monitoring as a safety check may also make appointments feel more manageable.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my (or my child's) Lp(a) level, and how does it change our long-term risk profile?
  2. 2.Since standard risk calculators don't work for FH, can you show me my 'FH-Risk-Score' or 'SAFEHEART' score?
  3. 3.How often should my child have an echocardiogram to check their aortic valve and aortic root?
  4. 4.Is a Coronary Artery Calcium (CAC) score appropriate for me at this stage, and what would a score of zero actually mean for my treatment?
  5. 5.Can you refer us to a counselor or support group that specializes in the psychological impact of chronic genetic conditions?
  6. 6.What other 'non-cholesterol' factors (like blood pressure or blood sugar) should we be monitoring more closely because of my FH?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia.

    Lefort B, Saheb S, Bruckert E, et al.

    Atherosclerosis 2015; (239(1)):158-62.

    PMID: 25608117
  2. 2

    Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia.

    Gallo A, Mszar R, Miname MH

    Current atherosclerosis reports 2022; (24(6)):407-418 doi:10.1007/s11883-022-01017-7.

    PMID: 35386094
  3. 3

    Association of Low-Density Lipoprotein Cholesterol With Risk of Aortic Valve Stenosis in Familial Hypercholesterolemia.

    Mundal LJ, Hovland A, Igland J, et al.

    JAMA cardiology 2019; (4(11)):1156-1159 doi:10.1001/jamacardio.2019.3903.

    PMID: 31617858
  4. 4

    Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.

    Vuorio A, Watts GF, Kovanen PT

    Atherosclerosis 2019; (281()):25-30 doi:10.1016/j.atherosclerosis.2018.11.040.

    PMID: 30616181
  5. 5

    Aortic Stenosis in Homozygous Familial Hypercholesterolemia: The Canadian HoFH Registry.

    Erzingatzian A, Al-Baldawi Z, Ruel I, et al.

    JACC. Advances 2026; (5(2)):102505 doi:10.1016/j.jacadv.2025.102505.

    PMID: 41579830
  6. 6

    Homozygous Familial Hypercholesterolemia in Canada: An Observational Study.

    Brown L, Ruel I, Baass A, et al.

    JACC. Advances 2023; (2(3)):100309 doi:10.1016/j.jacadv.2023.100309.

    PMID: 38939573
  7. 7

    Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia.

    Ellis KL, Pérez de Isla L, Alonso R, et al.

    Journal of the American College of Cardiology 2019; (73(9)):1029-1039 doi:10.1016/j.jacc.2018.12.037.

    PMID: 30846097
  8. 8

    Risk of cardiovascular disease with lipoprotein(a) in familial hypercholesterolemia: a review.

    Watanabe J, Hamasaki M, Kotani K

    Archives of medical sciences. Atherosclerotic diseases 2020; (5()):e148-e152 doi:10.5114/amsad.2020.97105.

    PMID: 32832714
  9. 9

    Lipoprotein(a) in familial dyslipidemias: The effect on cardiovascular prognosis in patients with familial hypercholesterolemia or familial combined hyperlipidemia.

    Skoumas I, Andrikou I, Simantiris S, et al.

    Nutrition, metabolism, and cardiovascular diseases : NMCD 2025; (35(7)):103867 doi:10.1016/j.numecd.2025.103867.

    PMID: 39986939
  10. 10

    Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.

    Kronenberg F, Mora S, Stroes ESG, et al.

    European heart journal 2022; (43(39)):3925-3946 doi:10.1093/eurheartj/ehac361.

    PMID: 36036785
  11. 11

    Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.

    Alhomoud IS, Talasaz A, Mehta A, et al.

    Pharmacotherapy 2023; (43(10)):1051-1063 doi:10.1002/phar.2851.

    PMID: 37464942
  12. 12

    Familial hypercholesterolemia: Review of diagnosis, screening, and treatment.

    Turgeon RD, Barry AR, Pearson GJ

    Canadian family physician Medecin de famille canadien 2016; (62(1)):32-7.

    PMID: 26796832
  13. 13

    The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia.

    Gallo A, Pérez de Isla L, Charrière S, et al.

    JACC. Cardiovascular imaging 2021; (14(12)):2414-2424 doi:10.1016/j.jcmg.2021.06.011.

    PMID: 34274263
  14. 14

    Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study).

    Pérez de Isla L, Alonso R, Mata N, et al.

    Circulation 2017; (135(22)):2133-2144 doi:10.1161/CIRCULATIONAHA.116.024541.

    PMID: 28275165
  15. 15

    Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia.

    Paquette M, Bernard S, Cariou B, et al.

    Arteriosclerosis, thrombosis, and vascular biology 2021; (41(10)):2632-2640 doi:10.1161/ATVBAHA.121.316106.

    PMID: 34433300
  16. 16

    Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy.

    Miname MH, Bittencourt MS, Moraes SR, et al.

    JACC. Cardiovascular imaging 2019; (12(9)):1797-1804 doi:10.1016/j.jcmg.2018.09.019.

    PMID: 30448145
  17. 17

    Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study.

    Pérez de Isla L, Alonso R, Muñiz-Grijalvo O, et al.

    Journal of clinical lipidology 2018; (12(4)):948-957 doi:10.1016/j.jacl.2018.04.003.

    PMID: 29753733
  18. 18

    Aortic Root Calcification Score as an Independent Factor for Predicting Major Adverse Cardiac Events in Familial Hypercholesterolemia.

    Okada H, Tada H, Hayashi K, et al.

    Journal of atherosclerosis and thrombosis 2018; (25(7)):634-642 doi:10.5551/jat.42705.

    PMID: 29321389
  19. 19

    A Comprehensive Neuropsychological Study of Familial Hypercholesterolemia and Its Relationship with Psychosocial Functioning: A Biopsychosocial Approach.

    Chan MF, Ganesh A, Mahadevan S, et al.

    Brain sciences 2022; (12(9)) doi:10.3390/brainsci12091127.

    PMID: 36138863
  20. 20

    Cholesterol-lowering therapy from childhood/adolescence and long-term outcomes in familial hypercholesterolaemia: the SAFEHEART study.

    Vallejo-Vaz AJ, Arroyo-Olivares R, Alonso R, et al.

    European heart journal 2026; doi:10.1093/eurheartj/ehag349.

    PMID: 42290618
  21. 21

    Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia.

    Watts GF, Sullivan DR, Hare DL, et al.

    Heart, lung & circulation 2021; (30(3)):324-349 doi:10.1016/j.hlc.2020.09.943.

    PMID: 33309206
  22. 22

    Facilitators and Barriers to Uptake of Genetic and Cascade Testing in Familial Hypercholesterolemia: a Systematic Review.

    Lenin C, Lim PXH, Nastar A, et al.

    International journal of behavioral medicine 2026; (33(1)):69-82 doi:10.1007/s12529-025-10357-y.

    PMID: 40199835
  23. 23

    A qualitative study of perceptions of the care pathway for familial hypercholesterolemia: screening, diagnosis, treatment, and family cascade screening.

    Pettit AR, Klaiman T, Kersting RC, et al.

    Implementation science communications 2024; (5(1)):135 doi:10.1186/s43058-024-00670-0.

    PMID: 39623509

This page is for informational purposes only and does not constitute medical advice. Your cardiology team can recommend the right monitoring schedule and tests for you or your child.

Get notified when new evidence is published on Familial hypercholesterolemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.